ClinicalTrials.gg
RecruitingNCT07914218Updated Nov 3, 2026

Rural Veteran and Care Partner Walking Program

An interventional study of Telerehabilitation Physical Activity Behavioral Intervention in Mild Cognitive Impairment (MCI), sponsored by Creighton University. Recruiting at 1 site in United States. Open to participants aged 19 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Creighton University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
19 Years to 90 Years
Sex
All
01

Study summary

The purpose of this study is to determine the practicality/feasibility of a virtual physical activity intervention to improve daily steps for Veterans with mild cognitive impairment and their care partners living in rural areas.

Participation includes:

  • Complete a 6-week walking program
  • Complete 2 testing visits (1 before and 1 after the 6-week walking program) consisting of various surveys and questionnaires
  • Complete a semi-structured interview on feasibility and feedback of the intervention
  • Potentially serve on an advisory board with the research team to assist with implementing the walking program adaptations
02

Conditions studied

  • Mild Cognitive Impairment (MCI)

Keywords

  • mild cognitive impairment
  • physical activity
  • veterans
  • walking
  • care partners
  • dyads
03

In context

Cognitive Dysfunction

3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.

This study's planned enrollment of 12 is below the median of 64 across 2,794 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Creighton University is the lead sponsor of 129 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Veterans:

  • 60-95 years of age
  • Mild cognitive impairment as staged by Clinical Dementia Rating (CDR, a gold standard cognitive outcome in ADRD clinical research) score of 0.5 or equivalent
  • Characterized as underactive by the Telephone Assessment of Physical Activity (TAPA)
  • Have a care partner willing to participate in physical activity and assist the participant
  • Own a smartphone or tablet and willing to download a fitness tracker application
  • Live in a rural area according to the VA Office of Rural Health rurality calculator

Inclusion Criteria for Veterans \& Care Providers:

  • No self-reported falls in the last year
  • Able to walk across a room in the home with no assistive device(s)
  • Stable doses of medication over the previous 30 days
  • Pass the Physical Activity Readiness Questionnaire+ (answering "no" to questions are pages 1-3)
  • Interaction as a dyad (Veteran and care partner) at least on a weekly basis

Inclusion Criteria for Veterans \& Care Providers:

  • 19 years of age or older
  • No cognitive impairment as indicated by a score of \< 1 on the AD8 Dementia Screening Interview

Exclusion Criteria for Veterans \& Care Providers:

  • Neurodegenerative or acute neurological diagnoses (e.g., Parkinson's disease, stroke, traumatic brain injury)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Field Testing Group

    Behavioral: Telerehabilitation Physical Activity Behavioral Intervention

Interventions

  • BehavioralTelerehabilitation Physical Activity Behavioral Intervention

    Six dyads (n=12) will complete TPAB field testing and will undergo testing at baseline and post-intervention. Consent, baseline testing, intervention delivery, and post-testing will be conducted virtually via Microsoft Teams and data recorded in VA REDCap. Testing sessions will not be recorded, with the exception of semi-structured interviews during post-testing. The testing procedures will take approximately 2 hours to complete at each testing time point. The TPAB intervention will involve weekly 30-minute sessions with study personnel for 6 weeks. Due to the 7-day activity monitor data collection prior to and following the 6-week TPAB intervention, participants will be enrolled in the study for approximately 8 weeks. Three dyads will be asked to join the advisory board with the research team to assist with implementing the walking program adaptations based on the collective feedback across the 16 dyads.

06

What researchers measure

Primary outcomes

  1. Weekly Session Attendance

    The total number of sessions attended by dyads will be reported as a percentage of the 6 weekly sessions. Ranges of attendance could be 0% (not attending any sessions) to 100% attending all session. Attendance will be used to evaluate participant engagement and practicality of implementation.

    Time frame: From enrollment to end of the 6-week intervention

  2. Study Retention

    Defined as continued participation through the study completion. Calculated using withdrawal and completion records. Higher retention (such as 100% retention indicating all dyads that enrolled in the study, completed the study) supports intervention feasibility.

    Time frame: From enrollment to end of intervention at 8 weeks

  3. Intrinsic Motivation Inventory (IMI)

    Evaluates participant interest, enjoyment, perceived value, and engagement with the intervention. The IMI is comprised of 7 statements related to interest/enjoyment that the participant indicates how true the statement is to them regarding their experience participating in the intervention. Each statement is scored on a 1-7 scale and an average is computed across all the questions to determine the IMI score. Higher scores indicate greater intervention acceptability.

    Time frame: Post-intervention (week 8)

  4. Number of participants with study-related adverse events

    Includes falls, injuries, medical issues, skin irritation, or other unintended consequences. Used to evaluate intervention safety.

    Time frame: From enrollment to end of intervention at 8 weeks

  5. Average Daily Stepping

    Objective measure of physical activity captured through Fitbit devices. Average daily step counts are computed in the Fitbit application and will be recorded for each day and averaged over the 7-day monitoring period before and after the intervention provide proof-of-concept evidence of behavior change.

    Time frame: Pre (before starting the 6-week walking program) and Post Intervention (following completion of the 6-week walking program)

  6. Qualitative Intervention Feasibility Outcomes

    Interviews evaluating demand, implementation, practicality, acceptability, adaptation, and integration. Findings will guide refinement of the intervention for future trials.

    Time frame: Post-intervention (for feedback)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 16 months after the start.

Of 1,442 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 16 months is below that.

Counting every sponsor, half of 1,511 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Nov 3, 2026
StartActual
Jun 12, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07914218
Collaborators
Iowa City VA Health Care System
Responsible party
Sponsor
First posted
Nov 3, 2026
Start date
Jun 12, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Rashelle Hoffman, PT, DPT, PhD
Contact
rashellehoffman@creighton.edu
402-280-5691

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion